177 related articles for article (PubMed ID: 36322904)
1. Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.
Nakajima Y; Takeyama M; Oda A; Shimonishi N; Nogami K
Blood Adv; 2023 Apr; 7(8):1436-1445. PubMed ID: 36322904
[TBL] [Abstract][Full Text] [Related]
2. The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.
Nakajima Y; Oda A; Baatartsogt N; Kashiwakura Y; Ohmori T; Nogami K
Blood Adv; 2024 May; ():. PubMed ID: 38820442
[TBL] [Abstract][Full Text] [Related]
3. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB
J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII A3 domain residues 1793-1795 represent a factor IXa-interactive site in the tenase complex.
Takeyama M; Furukawa S; Sasai K; Horiuchi K; Nogami K
Biochim Biophys Acta Gen Subj; 2023 Aug; 1867(8):130381. PubMed ID: 37207906
[TBL] [Abstract][Full Text] [Related]
5. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
Wakabayashi H; Fay PJ
J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
[TBL] [Abstract][Full Text] [Related]
6. Hydrogen-Deuterium Exchange Mass Spectrometry Identifies Activated Factor IX-Induced molecular Changes in Activated Factor VIII.
van Galen J; Freato N; Przeradzka MA; Ebberink EHTM; Boon-Spijker M; van der Zwaan C; van den Biggelaar M; Meijer AB
Thromb Haemost; 2021 May; 121(5):594-602. PubMed ID: 33302303
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of platelet receptor-mediated factor VIII binding.
Ahmad SS; Scandura JM; Walsh PN
J Biol Chem; 2000 Apr; 275(17):13071-81. PubMed ID: 10777612
[TBL] [Abstract][Full Text] [Related]
8. Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.
Wakabayashi H; Monaghan M; Fay PJ
J Biol Chem; 2014 May; 289(20):14020-9. PubMed ID: 24692542
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
[TBL] [Abstract][Full Text] [Related]
10. Maturation of coagulation factor IX during Xase formation as deduced using factor VIII-derived peptides.
Fang H; Zögg T; Brandstetter H
FEBS Open Bio; 2019 Aug; 9(8):1370-1378. PubMed ID: 31077577
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII lacking the C2 domain retains cofactor activity in vitro.
Wakabayashi H; Griffiths AE; Fay PJ
J Biol Chem; 2010 Aug; 285(33):25176-84. PubMed ID: 20529839
[TBL] [Abstract][Full Text] [Related]
12. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.
Jenkins PV; Freas J; Schmidt KM; Zhou Q; Fay PJ
Blood; 2002 Jul; 100(2):501-8. PubMed ID: 12091341
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
[TBL] [Abstract][Full Text] [Related]
14. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis.
Fay PJ; Beattie TL; Regan LM; O'Brien LM; Kaufman RJ
J Biol Chem; 1996 Mar; 271(11):6027-32. PubMed ID: 8626386
[TBL] [Abstract][Full Text] [Related]
15. Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa.
Griffiths AE; Rydkin I; Fay PJ
J Biol Chem; 2013 May; 288(21):15057-64. PubMed ID: 23580639
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of factor VIII by factor IXa.
O'Brien DP; Johnson D; Byfield P; Tuddenham EG
Biochemistry; 1992 Mar; 31(10):2805-12. PubMed ID: 1547220
[TBL] [Abstract][Full Text] [Related]
17. Contribution of the NH2-terminal EGF-domain of factor IXa to the specificity of intrinsic tenase.
Qureshi SH; Yang L; Rezaie AR
Thromb Haemost; 2012 Dec; 108(6):1154-64. PubMed ID: 23014580
[TBL] [Abstract][Full Text] [Related]
18. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.
Duffy EJ; Parker ET; Mutucumarana VP; Johnson AE; Lollar P
J Biol Chem; 1992 Aug; 267(24):17006-11. PubMed ID: 1512239
[TBL] [Abstract][Full Text] [Related]
19. Factor IX mutants with enhanced catalytic activity.
Hartmann R; Dockal M; Kammlander W; Panholzer E; Nicolaes GA; Fiedler C; Rosing J; Scheiflinger F
J Thromb Haemost; 2009 Oct; 7(10):1656-62. PubMed ID: 19656280
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
